+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serogroup C meningococci in Italy in the era of conjugate menC vaccination



Serogroup C meningococci in Italy in the era of conjugate menC vaccination



Bmc Infectious Diseases 9: 135



To assess changes in the pattern of Invasive Meningococcal Disease (IMD) in Italy after the introduction of conjugate menC vaccine in the National Vaccine Plan 2005-2007 and to provide information for developing timely and appropriate public health interventions, analyses of microbiological features of isolates and clinical characteristics of patients have been carried out. In Italy, the number of serogroup C meningococci fell progressively following the introduction of the MenC conjugate vaccine, recommended by the Italian Ministry of Health but implemented according to different regional strategies. IMD cases from January 2005 through July 2008 reported to the National Meningococcal Surveillance System were considered for this study. Serogrouping and sero/subtyping were performed on 179 serogroup C strains received at the National Reference Laboratory of the Istituto Superiore di Sanità. Antibiotic susceptibility testing was possible for 157 isolates. MLST (Multilocus sequence typing), porA VRs (Variable Region) typing, PFGE (Pulsed Field Gel Electrophoresis), VNTR (Variable Number Tandem Repeats) analyses were performed on all C:2a and C:2b meningococci (n = 147), following standard procedures. In 2005 and 2008, IMD showed an incidence of 0.5 and 0.3 per 100,000 inhabitants, respectively. While the incidence due to serogroup B remained stable, IMD incidence due to serogroup C has decreased since 2006. In particular, the decrease was significant among infants. C:2a and C:2b were the main serotypes, all C:2a strains belonged to ST-11 clonal complex and all C:2b to ST-8/A4. Clinical manifestations and outcome of infections underlined more severe disease caused by C:2a isolates. Two clusters due to C:2a/ST-11 meningococci were reported in the North of Italy in December 2007 and July 2008, respectively, with a high rate of septicaemia and fatal outcome. Public health surveillance of serogroup C invasive meningococcal disease and microbiological/molecular characterization of the isolates requires particular attention, since the hyper-invasive ST-11 predominantly affected adolescents and young adults for whom meningococcal vaccination was not recommended in the 2005-2007 National Vaccine Plan.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055724174

Download citation: RISBibTeXText

PMID: 19698137

DOI: 10.1186/1471-2334-9-135


Related references

Genetic and antigenic characterization of Canadian invasive Neisseria meningitidis serogroup C (MenC) case isolates in the post-MenC conjugate vaccine era, 2009-2013. Journal of Medical Microbiology 64(Pt 2): 174-179, 2015

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320): 1829-1831, 2002

Young-adult carriers of Neisseria meningitidis in Puglia (Italy): will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?. Human Vaccines 6(12): 1025-1027, 2010

Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunology & Medical Microbiology 28(3): 189-191, 2000

Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier. Fems Immunology and Medical Microbiology 46(3): 386-392, 2006

Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. Pediatric Infectious Disease Journal 32(6): 675-681, 2013

Serum opsonins to serogroup B meningococci after disease and vaccination. Niph Annals 14(2): 157-65; Discussion 166-7, 1991

Multi-locus sequence analysis of meningococci in Scotland before, during and after the introduction of meningococcal serogroup C conjugate vaccines. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 363, 2002

Characterization of invasive serogroup Y meningococci in Italy: prevalence of ST-23 Complex/Cluster A3. New Microbiologica 31(4): 467-472, 2008

Human opsonins to meningococci after vaccination with a serogroup acyw135 polysaccharide serotype 2b 15 protein vaccine. Journal of Microbiology 52(3): 259, 1986

Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction. Journal of Immunology Research 2015: 710656-710656, 2016

Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clinical and Diagnostic Laboratory Immunology 11(6): 1100-1104, 2004

Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines. Clinical and Vaccine Immunology 23(7): 555-563, 2016

Meningococcal serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go?. Canadian Journal of Public Health 101(1): 12-14, 2011